Numbers of participants, baseline characteristics, and numbers of death during follow up in women
| Number of deaths | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Study | Baseline numbers | Age range (years) | SBP, mean (SD) (mm Hg) | Serum TC, mean (SD) (mmol/l) | Smoking rate (%) | DM rate (%) | Median follow up (years) | All | CHD | CHD rate* |
| *Age standardised CHD mortality per 1000 person years. | ||||||||||
| NHANES I | 5378 | 35–74 | 138 (25) | 5.98 (1.26) | 26 | 4.5 | 19 | 1660 | 480 | 1.8 |
| NHANES II | 3994 | 35–74 | 134 (24) | 6.09 (1.30) | 27 | 6.3 | 14 | 751 | 199 | 1.0 |
| Framingham cohort | 2625 | 35–74 | 131 (21) | 5.76 (1.15) | 39 | 2.9 | 19 | 603 | 90 | 0.8 |
| Tecumseh community health study | 1286 | 35–74 | 141 (25) | 5.91 (1.21) | 32 | 4.0 | 19 | 250 | 77 | 2.1 |
| Renfrew and Paisley study | 8265 | 45–64 | 150 (25) | 6.42 (1.10) | 47 | 1.2 | 17 | 1878 | 562 | 2.2 |
| Norwegian counties study | 23863 | 35–49 | 131 (18) | 6.26 (1.23) | 37 | 0.5 | 17 | 1144 | 134 | 0.6 |
| Iceland Reykjavik study | 8899 | 36–74 | 137 (20) | 6.59 (1.22) | 38 | 1.4 | 17 | 1314 | 266 | 0.9 |
| HDFP (regular care) | 2227 | 35–69 | 163 (24) | 6.22 (1.28) | 32 | 8.2 | 8 | 251 | 66 | 2.0 |
| Total | 56535 | 7821 | 1874 | |||||||